Author Archives: Catarina Silva, MSc

Ixekizumab Benefits Ankylosing Spondylitis Patients Who Failed to Respond to Standard Therapy, Phase 3 Study Shows

Ankylosing spondylitis (AS) patients who have failed to respond to standard therapy may benefit from treatment with ixekizumab (Taltz by Eli Lilly), Phase 3 study results show. The study, “Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a…

Low Levels of Specific Immune Cell Linked to Ankylosing Spondylitis Manifestations, Mouse Study Suggests

Malfunction of the ankylosing spondylitis-associated gene, ERAP1, is connected to the loss of a certain type of immune cell, which seems to contribute to the inflammation process associated with the disease, according to a mouse study. Researchers now want to move to human trials in the coming years to validate…